Drug eluting stent implantation in patients requiring concomitant vitamin K antagonist therapy. One-year outcome of the worldwide e-SELECT registry.
暂无分享,去创建一个
M. Jeong | F. Neumann | S. Ellis | D. Holmes | M. Nyåkern | S. Brugaletta | M. Sabaté | V. Džavík | P. Urban | C. Spaulding | A. Abizaid | S. Worthley | A. Banning | A. Bartorelli | R. Gao | H. Stoll | V. Legrand
[1] P. Serruys,et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial , 2012, The Lancet.
[2] G. Lip,et al. Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score ? , 2012 .
[3] Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .
[4] M. Jeong,et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. , 2011, Journal of the American College of Cardiology.
[5] M. Jeong,et al. Sirolimus-eluting coronary stents in octogenarians: a 1-year analysis of the worldwide e-SELECT Registry. , 2011, JACC. Cardiovascular interventions.
[6] A. Kastrati,et al. Everolimus-Eluting Versus Sirolimus-Eluting StentsClinical Perspective , 2011 .
[7] A. Kastrati,et al. Everolimus-Eluting Versus Sirolimus-Eluting Stents: A Meta-Analysis of Randomized Trials , 2011, Circulation. Cardiovascular interventions.
[8] Deepak L. Bhatt,et al. Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting , 2011, Thrombosis and Haemostasis.
[9] Z. Wang,et al. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. , 2011, International journal of cardiology.
[10] M. Jeong,et al. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. , 2011, Journal of the American College of Cardiology.
[11] M. de Antonio,et al. Endothelial progenitor cell capturing stent and short dual antiplatelet therapy in patients on chronic anti-vitamin k regimen undergoing percutaneous coronary interventions: long-term outcomes of a single centre registry. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[12] P. Kirchhof,et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) a , 2010, European heart journal.
[13] C. Macaya,et al. Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis. , 2010, Journal of the American College of Cardiology.
[14] P. Kirchhof,et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting , 2009, Thrombosis and Haemostasis.
[15] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[16] C. Macaya,et al. New stent implantation for recurrences after stenting for in-stent restenosis: implications of a third metal layer in human coronary arteries. , 2009, Journal of the American College of Cardiology.
[17] G. Lip,et al. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. , 2008, European heart journal.
[18] M. Niemelä,et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. , 2008, European heart journal.
[19] G. Lip,et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. , 2008, Journal of the American College of Cardiology.
[20] E. Romagnoli,et al. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. , 2008, JACC. Cardiovascular interventions.
[21] J. Navarro,et al. Morbilidad y mortalidad en pacientes con tratamiento anticoagulante oral , 2007 .
[22] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[23] M. Niemelä,et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. , 2007, European heart journal.
[24] J. Fontcuberta,et al. [Morbidity and mortality in patients treated with oral anticoagulants]. , 2007, Revista espanola de cardiologia.
[25] S. Steinhubl,et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. , 2006, The New England journal of medicine.
[26] Fesc,et al. Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice: One-Year Follow-Up of the e-Cypher Registry , 2006, Circulation.
[27] F. Fernández‐Avilés,et al. Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.
[28] Patrick W. Serruys,et al. A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization , 2002 .